Financial Ratios Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:48:09 06/02/2026 GMT			5-day change	1st Jan Change
104.31 ^CAD	0.00%		-2.94%	-5.54%

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT

2b62756f763bbc5b49011d1.dvHZRf-Y9kZ2PwuIFfH7GGLygvqC-IvRlwSr5N4iSNE.GIWPNbvZnAwvcn3FLamLShu9xZbGkNOr2W3MnIsPf6FGgJUhu-umKzRZTg

Published financial data: BRIGHT MINDS BIOSCIENCES INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2021	2022	2023	2024	2025
Selling General & Admin Expenses, Total	2.31M	2.57M	2.21M	1.44M	2.53M
Stock-Based Compensation (IS)	-	-	-	-	-
R&D Expenses	6.31M	12.16M	4.98M	1.18M	11.08M
Other Operating Expenses, Total	8.62M	14.73M	7.2M	2.62M	13.61M
Operating Income	-8.62M	-14.73M	-7.2M	-2.62M	-13.61M
Interest Expense, Total	-	-	-	-8.94K	-35.85K
Interest And Investment Income	-	-	-	30.13K	1.52M
Net Interest Expenses	-	-	-	21.19K	1.48M
Currency Exchange Gains (Loss)	154K	12.15K	14.19K	-9.31K	189K
Other Non Operating Income (Expenses)	-182K	-243K	-187K	-197K	-288K
EBT, Excl. Unusual Items	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Asset Writedown	-	-2K	-	-	-
EBT, Incl. Unusual Items	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Earnings From Continuing Operations	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Net Income to Company	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Net Income - (IS)	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Net Income to Common Incl Extra Items	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Net Income to Common Excl. Extra Items	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Per Share Items
Net EPS - Basic	-4.82	-6.06	-1.98	-0.65	-1.78
Basic EPS - Continuing Operations	-4.82	-6.06	-1.98	-0.65	-1.78
Basic Weighted Average Shares Outstanding	1.79M	2.47M	3.72M	4.31M	6.88M
Net EPS - Diluted	-4.82	-6.06	-1.98	-0.65	-1.78
Diluted EPS - Continuing Operations	-4.82	-6.06	-1.98	-0.65	-1.78
Diluted Weighted Average Shares Outstanding	1.79M	2.47M	3.72M	4.31M	6.88M
Normalized Basic EPS	-3.01	-3.79	-1.24	-0.41	-1.11
Normalized Diluted EPS	-3.01	-3.79	-1.24	-0.41	-1.11
Supplemental Items
EBITA	-8.62M	-14.73M	-7.2M	-2.62M	-13.61M
EBIT	-8.62M	-14.73M	-7.2M	-2.62M	-13.61M
Normalized Net Income	-5.41M	-9.35M	-4.61M	-1.75M	-7.64M
Interest on Long-Term Debt	-	2.17K	19.75K	8.94K	35.85K
Supplemental Operating Expense Items
Marketing Expenses	848K	552K	119K	41.6K	430K
Selling and Marketing Expenses	852K	552K	119K	41.6K	430K
General and Administrative Expenses	1.46M	1.93M	2.08M	1.4M	2.1M
Research And Development Expense From Footnotes	6.31M	12.18M	5M	1.18M	11.08M
Net Rental Expense, Total	-	92.37K	15.17K	-	-
Stock-Based Comp., R&D Exp. (Total)	709K	772K	-48.13K	298K	2.62M
Stock-Based Comp., S&M Exp. (Total)	3.7K	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	168K	131K	1.2M	542K	560K
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	881K	902K	1.15M	840K	3.18M

Fiscal Period: September	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	19.76M	11.63M	6.75M	5.72M	82.91M
Total Cash And Short Term Investments	19.76M	11.63M	6.75M	5.72M	82.91M
Other Receivables	110K	156K	36.98K	50.22K	413K
Total Receivables	110K	156K	36.98K	50.22K	413K
Prepaid Expenses	168K	164K	27.69K	217K	988K
Total Current Assets	20.04M	11.95M	6.81M	5.99M	84.31M
Gross Property Plant And Equipment	-	145K	-	-	-
Accumulated Depreciation	-	-6.04K	-	-	-
Net Property Plant And Equipment	-	139K	66.41K	118K	112K
Other Intangibles, Total	2K	-	-	-	-
Total Assets	20.04M	12.09M	6.88M	6.1M	84.42M
Liabilities
Accounts Payable, Total	597K	1.25M	182K	408K	1.71M
Accrued Expenses, Total	42K	158K	25K	41.75K	541K
Current Portion of Leases	-	67.93K	73.55K	79.38K	84.53K
Total Current Liabilities	639K	1.47M	281K	529K	2.34M
Long-Term Leases	-	71.98K	-	39.58K	41.25K
Total Liabilities	639K	1.54M	281K	568K	2.38M
Common Stock, Total	27.08M	32.24M	33.91M	35.42M	123M
Retained Earnings	-9.21M	-24.17M	-31.55M	-34.35M	-46.58M
Comprehensive Income and Other	1.53M	2.48M	4.23M	4.46M	5.37M
Total Common Equity	19.4M	10.54M	6.6M	5.54M	82.04M
Total Equity	19.4M	10.54M	6.6M	5.54M	82.04M
Total Liabilities And Equity	20.04M	12.09M	6.88M	6.1M	84.42M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.37M	3.74M	4.46M	6.99M	7.79M
ECS Total Common Shares Outstanding	2.37M	3.52M	3.77M	4.52M	7.64M
Book Value / Share	8.2	3	1.75	1.22	10.74
Tangible Book Value	19.4M	10.54M	6.6M	5.54M	82.04M
Tangible Book Value Per Share	8.2	3	1.75	1.22	10.74
Total Debt	0	140K	73.55K	119K	126K
Net Debt	-19.76M	-11.49M	-6.67M	-5.6M	-82.78M
Debt Equivalent Oper. Leases	-	739K	121K	-	-
Account Code - Inventory Valuation	3	-	3	3	3
Full Time Employees	-	-	-	1	26

Fiscal Period: September	2021	2022	2023	2024	2025
Net Income	-8.65M	-14.96M	-7.37M	-2.8M	-12.23M
Depreciation & Amortization - CF	-	6.04K	72.45K	73.36K	76.87K
Depreciation & Amortization, Total	-	6.04K	72.45K	73.36K	76.87K
Asset Writedown & Restructuring Costs	-	2K	-	-	-
Stock-Based Compensation (CF)	881K	902K	1.15M	840K	3.18M
Other Operating Activities, Total	145K	-257K	65.1K	-1.18K	-277K
Change In Accounts Payable	506K	766K	-1.2M	242K	1.69M
Change in Other Net Operating Assets	-200K	-41.86K	256K	-202K	-1.13M
Cash from Operations	-7.32M	-13.59M	-7.02M	-1.85M	-8.69M
Long-Term Debt Repaid, Total	-	-7.16K	-86.11K	-89.73K	-100K
Total Debt Repaid	-	-7.16K	-86.11K	-89.73K	-100K
Issuance of Common Stock	27.84M	6M	1.47M	900K	86.03M
Other Financing Activities, Total	-1.79M	-800K	805K	302	-360K
Cash from Financing	26.06M	5.2M	2.19M	811K	85.57M
Foreign Exchange Rate Adjustments	224K	259K	-45.35K	11.72K	313K
Net Change in Cash	18.96M	-8.13M	-4.88M	-1.03M	77.19M
Supplemental Items
Levered Free Cash Flow	-4.22M	-7.58M	-4.22M	-688K	-4.6M
Unlevered Free Cash Flow	-4.22M	-7.58M	-4.22M	-682K	-4.58M
Change In Net Working Capital	-288K	-724K	942K	-39.81K	-667K
Net Debt Issued / Repaid	-	-7.16K	-86.11K	-89.73K	-100K

Fiscal Period: September	2021	2022	2023	2024	2025
Profitability
Return on Assets	-51.52	-57.32	-47.45	-25.19	-18.8
Return on Total Capital	-53.54	-61.21	-51.86	-26.53	-19.38
Return On Equity %	-85.94	-99.95	-86.02	-46.18	-27.93
Return on Common Equity	-85.94	-99.95	-86.02	-46.18	-27.93
Short Term Liquidity
Current Ratio	31.38	8.11	24.26	11.32	36.1
Quick Ratio	31.12	8	24.16	10.91	35.68
Operating Cash Flow to Current Liabilities	-11.46	-9.23	-25.01	-3.5	-3.72
Long Term Solvency
Total Debt/Equity	-	1.33	1.11	2.15	0.15
Total Debt / Total Capital	-	1.31	1.1	2.1	0.15
LT Debt/Equity	-	0.68	-	0.71	0.05
Long-Term Debt / Total Capital	-	0.67	-	0.7	0.05
Total Liabilities / Total Assets	3.19	12.78	4.08	9.31	2.82
EBIT / Interest Expense	-	-	-	-292.52	-379.74
EBITDA / Interest Expense	-	-	-	-284.32	-377.6
(EBITDA - Capex) / Interest Expense	-	-	-	-284.32	-377.6
Total Debt / EBITDA	-	-0.01	-0.01	-0.05	-0.01
Net Debt / EBITDA	-	0.78	0.94	2.2	6.12
Total Debt / (EBITDA - Capex)	-	-0.01	-0.01	-0.05	-0.01
Net Debt / (EBITDA - Capex)	-	0.78	0.94	2.2	6.12
Growth Over Prior Year
EBITA, 1 Yr. Growth %	1.72K	70.84	-51.13	-63.66	418.52
EBIT, 1 Yr. Growth %	1.72K	70.84	-51.13	-63.66	418.52
Earnings From Cont. Operations, 1 Yr. Growth %	1.7K	72.99	-50.74	-61.99	336.46
Net Income, 1 Yr. Growth %	1.7K	72.99	-50.74	-61.99	336.46
Normalized Net Income, 1 Yr. Growth %	1.7K	72.97	-50.73	-61.99	336.46
Diluted EPS Before Extra, 1 Yr. Growth %	624.91	25.68	-67.28	-67.2	173.51
Net Property, Plant and Equip., 1 Yr. Growth %	-	-	-52.17	77.16	-4.84
Total Assets, 1 Yr. Growth %	2.18K	-39.69	-43.09	-11.26	1.28K
Tangible Book Value, 1 Yr. Growth %	2.57K	-45.66	-37.41	-16.09	1.38K
Common Equity, 1 Yr. Growth %	2.56K	-45.66	-37.41	-16.09	1.38K
Cash From Operations, 1 Yr. Growth %	2.44K	85.63	-48.3	-73.66	369.77
Levered Free Cash Flow, 1 Yr. Growth %	4.14K	79.45	-44.33	-83.68	569.17
Unlevered Free Cash Flow, 1 Yr. Growth %	4.14K	79.45	-44.33	-83.82	565.92
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	504.28	456.95	-8.63	-57.86	37.51
EBIT, 2 Yr. CAGR %	504.28	456.95	-8.63	-57.86	37.51
Earnings From Cont. Operations, 2 Yr. CAGR %	505.25	458.14	-7.68	-56.73	28.8
Net Income, 2 Yr. CAGR %	505.25	458.14	-7.68	-56.73	28.8
Normalized Net Income, 2 Yr. CAGR %	505.25	458.11	-7.68	-56.73	28.8
Diluted EPS Before Extra, 2 Yr. CAGR %	190.91	201.84	-35.88	-67.25	-5.28
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-	-7.95	29.84
Total Assets, 2 Yr. CAGR %	1.46K	270.56	-41.41	-28.93	250.32
Tangible Book Value, 2 Yr. CAGR %	2.02K	280.73	-41.68	-27.53	252.62
Common Equity, 2 Yr. CAGR %	1.97K	280.21	-41.68	-27.53	252.62
Cash From Operations, 2 Yr. CAGR %	662.08	586.39	-2.04	-63.1	11.24
Levered Free Cash Flow, 2 Yr. CAGR %	-	772.09	4.62	-69.86	4.49
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	772.09	4.62	-69.98	4.24
Compound Annual Growth Rate Over Three Years
EBITA, 3 Yr. CAGR %	-	296.6	147.49	-32.8	-2.6
EBIT, 3 Yr. CAGR %	-	296.6	147.49	-32.8	-2.6
Earnings From Cont. Operations, 3 Yr. CAGR %	-	298.68	148.51	-31.32	-6.51
Net Income, 3 Yr. CAGR %	-	298.68	148.51	-31.32	-6.51
Normalized Net Income, 3 Yr. CAGR %	-	298.67	148.51	-31.32	-6.5
Diluted EPS Before Extra, 3 Yr. CAGR %	-	119.92	43.92	-48.72	-33.55
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	-	-6.92
Total Assets, 3 Yr. CAGR %	-	428.26	98.45	-32.72	91.15
Tangible Book Value, 3 Yr. CAGR %	-	524.51	108.56	-34.16	98.17
Common Equity, 3 Yr. CAGR %	-	515.18	108.37	-34.16	98.17
Cash From Operations, 3 Yr. CAGR %	-	375.94	189.87	-36.77	-13.84
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	248.53	-43.69	-15.29
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	248.53	-43.84	-15.43
Compound Annual Growth Rate Over Five Years
EBITA, 5 Yr. CAGR %	-	-	-	61.77	95.65
EBIT, 5 Yr. CAGR %	-	-	-	61.77	95.65
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	64	91.06
Net Income, 5 Yr. CAGR %	-	-	-	64	91.06
Normalized Net Income, 5 Yr. CAGR %	-	-	-	64	91.06
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	2.68	21.74
Total Assets, 5 Yr. CAGR %	-	-	-	136.8	149.1
Tangible Book Value, 5 Yr. CAGR %	-	-	-	163.86	157.32
Common Equity, 5 Yr. CAGR %	-	-	-	161.49	157.18
Cash From Operations, 5 Yr. CAGR %	-	-	-	71.14	97.62
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	115.27
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	115.06